- Home
- GLMD vs KTTA Comparison
GLMD vs KTTA Comparison
Compare GLMD & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- KTTA
- Stock Information
- Founded
- GLMD 2000
- KTTA 2020
- Country
- GLMD Israel
- KTTA United States
- Employees
- GLMD N/A
- KTTA N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- KTTA Health Care
- Exchange
- GLMD Nasdaq
- KTTA Nasdaq
- Market Cap
- GLMD 3.0M
- KTTA 2.8M
- IPO Year
- GLMD 2014
- KTTA 2021
- Fundamental
- Price
- GLMD $1.81
- KTTA $0.73
- Analyst Decision
- GLMD Hold
- KTTA
- Analyst Count
- GLMD 1
- KTTA 0
- Target Price
- GLMD N/A
- KTTA N/A
- AVG Volume (30 Days)
- GLMD 364.3K
- KTTA 222.0K
- Earning Date
- GLMD 05-22-2025
- KTTA 08-12-2025
- Dividend Yield
- GLMD N/A
- KTTA N/A
- EPS Growth
- GLMD N/A
- KTTA N/A
- EPS
- GLMD N/A
- KTTA N/A
- Revenue
- GLMD N/A
- KTTA N/A
- Revenue This Year
- GLMD N/A
- KTTA N/A
- Revenue Next Year
- GLMD N/A
- KTTA N/A
- P/E Ratio
- GLMD N/A
- KTTA N/A
- Revenue Growth
- GLMD N/A
- KTTA N/A
- 52 Week Low
- GLMD $1.15
- KTTA $0.71
- 52 Week High
- GLMD $23.80
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- GLMD 61.13
- KTTA 33.06
- Support Level
- GLMD $1.63
- KTTA $0.71
- Resistance Level
- GLMD $1.94
- KTTA $0.80
- Average True Range (ATR)
- GLMD 0.12
- KTTA 0.04
- MACD
- GLMD 0.01
- KTTA 0.00
- Stochastic Oscillator
- GLMD 69.77
- KTTA 12.14
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).